Login / Signup

Comparison of clinical efficacy and safety of weekly glucagon-like peptide-1 receptor agonists dulaglutide and semaglutide in Japanese patients with type 2 diabetes: Randomized, parallel-group, multicentre, open-label trial (COMING study).

Tomohiko KimuraYukino KatakuraMasashi ShimodaFumiko KawasakiMizuho YamabeFuminori TatsumiMichihiro MatsukiYuichiro IwamotoTakatoshi AnnoYoshiro FushimiShinji KameiYukiko KimuraShuhei NakanishiTomoatsu MuneKohei KakuHideaki Kanetonull null
Published in: Diabetes, obesity & metabolism (2023)
This prospective trial showed that semaglutide has more pronounced glucose- and body mass index-lowering effects and reduces liver fat percentage and visceral fat area and that dulaglutide has less gastrointestinal symptoms and superior Diabetes Treatment-Related Quality of Life scores related to pain and gastrointestinal symptoms.
Keyphrases